Our findings otherwise revealed no associations between the immune microenvironment and TMB in non-hypermutant pedNST, suggesting TMB, with the exception of MMR-associated tumours, may not be an appropriate biomarker for immune checkpoint inhibitors in this population. The gene discussed is MRC1; the disease is neoplasm.